Millbrae, United States
Eikon Therapeutics, founded in 2019, is a United States-based late-stage clinical biopharmaceutical company with a focus on inventing and developing breakthrough therapeutics. The company is advancing therapies for patients with unmet medical needs and employs cutting-edge technology such as single-molecule imaging and machine learning to drive their discovery efforts, particularly in oncology and neurological disorders.
Their approach leverages immune response modulation and synthetic lethality to improve cancer therapies, positioning Eikon as a potentially transformative player in the biotechnology, health care, and life sciences industries. Their recent $350.70M Series D investment on 01 February 2025 demonstrates strong investor confidence, with participation from notable investors like Lux Capital, AME Cloud Ventures, General Catalyst, The Column Group, and Soros Capital Management, among others. Such funding underscores their capability to attract significant capital and propel their innovative programs and reach into global markets.
